AURA - Company ID 0001501796
The table below shows Aura Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$29.89M | -$23.36M | -$24.45M | -$16.41M | -$15.20M | -$5.14M |
| Capital expenditure | $102.00K | $187.00K | $88.00K | $109.00K | $599.00K | $71.00K |
| Investing cash flow | $54.90M | $29.81M | $9.40M | -$66.88M | -$25.50M | -$71.00K |
| Dividends paid | - | - | - |
Aura Biosciences, Inc. reported operating cash flow of -$84.74M for fiscal year 2025. That is down 6.2% from -$79.81M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$24.32M (FY 2020) to -$84.74M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $300.00K | $96.00K | $253.00K | $201.00K | $17.00K | $87.49M |